L
Laura Q.M. Chow
Researcher at University of Washington
Publications - 134
Citations - 17283
Laura Q.M. Chow is an academic researcher from University of Washington. The author has contributed to research in topics: Nivolumab & non-small cell lung cancer (NSCLC). The author has an hindex of 40, co-authored 128 publications receiving 14462 citations. Previous affiliations of Laura Q.M. Chow include Yale Cancer Center & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
TL;DR: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.
Journal ArticleDOI
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda,Laura Q.M. Chow,Claire Dees,Raanan Berger,Shilpa Gupta,Ravit Geva,Lajos Pusztai,Kumudu Pathiraja,Gursel Aktan,Jonathan D. Cheng,Vassiliki Karantza,Laurence Buisseret +11 more
TL;DR: This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC.
Journal ArticleDOI
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow,Robert I. Haddad,Shilpa Gupta,Amit Mahipal,Ranee Mehra,Makoto Tahara,Raanan Berger,Joseph Paul Eder,Barbara Burtness,Se-Hoon Lee,Bhumsuk Keam,Hyunseok Kang,Kei Muro,Jared Weiss,Ravit Geva,Chia-Chi Lin,Hyun Cheol Chung,Amy Meister,Marisa Dolled-Filhart,Kumudu Pathiraja,Jonathan D. Cheng,Tanguy Y. Seiwert +21 more
TL;DR: Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.
Journal ArticleDOI
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin,Roger B. Cohen,Matthew Eadens,Lia Gore,D. Ross Camidge,Sami Diab,Stephen Leong,Cindy L. O'Bryant,Laura Q.M. Chow,Natalie J. Serkova,N. J. Meropol,Nancy L. Lewis,E. Gabriela Chiorean,Floyd Fox,Hagop Youssoufian,E. K. Rowinsky,S. Gail Eckhardt +16 more
TL;DR: Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.